Immunosuppressants are used to control severe manifestations of allergic, autoimmune and transplant-related diseases. Some drugs have a diffuse effect on the immune system while others have specific targets. Drugs with diffuse effects are more likely to cause damaging adverse effects, but the effectiveness of the more specific drugs may be reduced if their action can be bypassed by alternative metabolic pathways. Treatment protocols therefore frequently use drug combinations to minimise adverse effects and to prevent resistance to treatment. Although protocols are essential to allow scientific evaluation, the clinician must be prepared to tailor treatment based on the ongoing assessment of drug effects, disease activity and the robustness of the individual patient.
Introduction
Many of the currently available immunosuppressants were developed for use in oncology or transplantation. As this treatment is potentially life-saving desperate measures can be justified. However, there are now over 80 autoimmune diseases and several common allergic conditions in which immunosuppressants could play a role although they may not be life-saving.
Some immunosuppressants act through immunodepletion of effector cells, while others are predominantly immunomodulatory, affecting the activity of cells, usually through cytokine inhibition. Immunosuppressants can be categorised as glucocorticoids, small molecules or proteins. 1 
Glucocorticoids
Corticosteroids are the mainstay of most immunosuppressive regimens in both the induction and maintenance phases. In high intravenous pulse doses (methylprednisolone 250-1000 mg daily for 1-3 days) they are directly lymphocytotoxic. In smaller doses, they are immunosuppressive and anti-inflammatory by limiting cytokine production. The required dose and duration of treatment therefore tends to be disease specific.
Some diseases, for example asthma, respond to a short course which can be abruptly stopped, but most rheumatic diseases require the dose to be very slowly tapered over months, However, they also have their own toxicities.
Patients prescribed corticosteroids should be told to expect the common early adverse effects, such as sweatiness, hoarse voice, loss of diurnal sleep patterns, and appetite stimulation.
Rarely, more serious acute psychiatric disturbances are seen such as agitation, aggression or psychosis. Long-term, and less reversible, adverse effects include Cushingoid appearance, proximal myopathy, hypertension, hyperlipidaemia, diabetes, cataract formation, peptic ulceration, osteopenia and aseptic necrosis of bone. (Table 1) The small molecule immunosuppressants include calcineurin inhibitors, such as cyclosporin, and antiproliferative drugs, such as sirolimus.
Small molecules

Calcineurin inhibitors
Since the 1980s, calcineurin inhibitors have been the main contributors to the success of solid organ transplantation, especially kidneys. By blocking interleukin-2 synthesis, they prevent activation of T-lymphocytes and are therefore useful in disorders of cell-mediated immunity. Calcineurin inhibitors have a proven role in the prevention of acute cellular rejection of transplanted organs, in psoriasis and in nephrotic syndrome. 
Mycophenolate mofetil
Since it was introduced into Australia in 1996 mycophenolate mofetil has largely replaced azathioprine in organ transplantation.
One advantage over azathioprine is that allopurinol can be used for gout prophylaxis without the need to reduce the dose of mycophenolate. Possibly because of its anti-B cell properties 2 mycophenolate seems particularly effective in severe forms of systemic lupus erythematosus. It is also gaining favour as a steroid-sparing drug in the maintenance phase of a number of immune disorders, particularly the vasculitides. 3 The main adverse effects are haematological and gastrointestinal. On higher doses a third of patients will develop
diarrhoea. An enteric-coated formulation of mycophenolate has been developed to try and reduce gastrointestinal adverse effects.
Therapeutic drug monitoring is available but not widely used.
Sirolimus and everolimus
These potent antiproliferative drugs have gained acceptance in renal transplantation as a strategy to minimise the use of calcineurin inhibitors in low immunological risk patients. 4 They have a decreased likelihood of causing hypertension and glucose intolerance. Although these drugs are associated with less nephrotoxicity than calcineurin antagonists, they potentiate the renal toxicity of cyclosporin and regular monitoring of renal function is recommended. Sirolimus and everolimus are generally avoided perioperatively because they can severely delay wound healing. They are potent inhibitors of intimal hyperplasia in arteries, and sirolimus-eluting intra-arterial stents are now used to reduce re-stenosis rates. However, they can increase serum cholesterol and lipids. The balance of the harm and benefit of continued treatment should be re-evaluated in patients who develop severe refractory hyperlipidaemia.
Therapeutic drug monitoring is essential because of the risk of toxicity such as anaemia, leucopenia and thrombocytopenia.
Cyclophosphamide
Cyclophosphamide is a cytotoxic drug. It is the drug of choice for Wegener's granulomatosis, but is also used in other vasculitides such as microscopic polyangiitis and systemic lupus erythematosus. 5 Monthly intravenous pulses are as effective as daily oral use in systemic lupus erythematosus, but allow a reduced total dosage. Cyclophosphamide is also used to induce sustained remission in relapsing nephrotic syndrome. Marrow suppression with neutropenia is common after six weeks of treatment and continuing more than six months runs the risk of gonadal suppression and infertility in both sexes.
Methotrexate
This antimetabolite is used in some autoimmune diseases including psoriasis, psoriatic arthritis, rheumatoid arthritis and Crohn's disease. As a disease-modifying antirheumatic drug, its use in combination with tumour necrosis factor inhibitors (such as infliximab or etanercept) or leflunomide has been shown to markedly improve symptoms in rheumatoid arthritis. 6
Proteins ( Table 2) Polyclonal antilymphocyte (antithymocyte) antibodies have been A new monoclonal antibody, alemtuzumab, is directed against a surface molecule (CD54), which is widely distributed on lymphocytes, macrophages and dendritic cells, thereby causing severe and long-lasting depletion of these cell lines. As a result, the risk of serious infection is increased. The use of this antibody is cautiously making the transition from immunoprophylaxis in transplant recipients to a wider use in immune diseases. 8 Two monoclonal antibodies against tumour necrosis factor, infliximab and adalimumab, and etanercept which prevents tumour necrosis factor binding to its receptor, are licensed for use in rheumatoid arthritis. They are also being used in ankylosing spondylitis, psoriatic arthritis and inflammatory bowel disease. 9 Infusion reactions are common. 
Using immunosuppressants -strategies and protocols
Treatment protocols are designed to:
(a) remove/suppress the predominant immune effectors and/or (b) resolve acute inflammation (c) prevent relapse.
To achieve (a) and (b), high doses are often used initially ('induction phase'). To achieve (c), lower doses of safer drugs are often chosen for the longer term ('maintenance phase').
Withdrawal of therapy is usually only considered after achieving clinical and laboratory evidence of sustained remission. Drugs are withdrawn gradually, one at a time and in the case of corticosteroids only after a long taper. 
Empiricism vs controlled trials
Choosing immunosuppressive regimens
In order to make sound judgements when choosing a treatment protocol the clinician has to consider the clinical trial evidence and then decide: 
Managing and monitoring patients taking immunosuppressants
Patients need to be under constant surveillance, usually by a partnership between the specialist and the general practitioner.
Frequency of visits depends on perceived level of risk, but typical parameters to monitor are summarised in Table 3 .
Patients may need prophylaxis against the adverse effects of their treatment (Table 4) .
Therapeutic drug monitoring is available now for a number of drugs, for example cyclosporin, tacrolimus, sirolimus and mycophenolate. This allows for 'concentration-controlled' regimens. Some common drugs, for example corticosteroids, still have no good measure of individual bioavailability.
Infection risk
Immunosuppression increases susceptibility to infections which can become life-threatening in a matter of hours. At first, common bacterial infections of wounds, chest or urine predominate, but after 1-2 months of therapy opportunistic infections emerge, particularly herpes viruses, pneumocystis pneumonia, fungi and atypical mycobacteria.
Vaccinations against influenza (injected) and pneumococcus are recommended in chronically immunosuppressed patients. 12 They are safe and reasonably effective when given in the stable maintenance phase. In general, live attenuated virus vaccines, such as varicella or measles, should not be given to immunosuppressed patients (or to close family contacts).
Cancer risk
In patients taking immunosuppressants, early cancers are often viral induced. They include lymphoproliferative disorders and cervical cancer. In the long term, nearly all common cancers are increased, but particularly skin cancers. After 20 years of immunoprophylaxis following renal transplant, 80% of Australian patients will have developed skin cancer. 
Conclusion
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